Tirzepatide: Evidence, Cost, Providers, and Safety
An independent resource on tirzepatide: what the trials actually found, what compounded products are and are not, what treatment really costs, and how to verify the pharmacy behind it.
Tirzepatide is a dual GIP and GLP-1 receptor agonist approved as Zepbound for chronic weight management and Mounjaro for type 2 diabetes. In SURMOUNT-1 it produced about 20.9% mean weight reduction at 15 mg over 72 weeks. Compounded tirzepatide is a different, non-FDA-approved product that has never been tested in a randomised trial, and this site keeps that distinction throughout.
Key takeaways
- Tirzepatide is approved as Zepbound (weight management) and Mounjaro (type 2 diabetes) — compounded versions are neither.
- 6 tirzepatide trials here carry verified registry and publication identifiers you can check.
- Stopping treatment produces substantial weight regain (SURMOUNT-4), so cost should be modelled over years.
- Provider prices are normalised before comparison, because advertised figures often exclude mandatory fees.
- This publication takes no money from any provider, pharmacy, or manufacturer.
| What tirzepatide is | Dual GIP/GLP-1 receptor agonist, injected once weekly |
|---|---|
| Approved brands | Zepbound (weight management), Mounjaro (type 2 diabetes) |
| Pivotal weight trial | SURMOUNT-1 — about 20.9% mean reduction at 15 mg, N=2,539 |
| Compounded status | Not FDA approved; never studied in a randomised trial |
| Dataset snapshot | 2026-07-22 |
| Methodology version | v1.0 |
Start with the complete guide See the trial evidence
Where should you start?
What does the tirzepatide evidence actually show?
In adults with obesity and without diabetes, SURMOUNT-1 recorded about 20.9% mean weight reduction at the 15 mg dose over 72 weeks against 3.1% on placebo. In adults who also have type 2 diabetes, SURMOUNT-2 recorded meaningfully less — roughly 12.8% to 14.7%. In the head-to-head SURMOUNT-5 trial, tirzepatide outperformed semaglutide on weight and waist circumference.
The most consequential finding for planning is SURMOUNT-4: people randomised to stop regained substantially, while those who continued held their loss. That makes tirzepatide a long-term treatment in practice, which is why this site models cost over years rather than months.
How is compounded tirzepatide different from Zepbound or Mounjaro?
Zepbound and Mounjaro are FDA-approved products: reviewed before marketing, manufactured under verified controls, and studied in the trials cited above. Compounded tirzepatide is prepared by a pharmacy, is not FDA approved, and has never been tested in a randomised trial. Concentration, excipients, and quality control can differ, and no study has established equivalence.
That does not automatically make compounded products unsafe. It means their performance is unmeasured, so verification of the pharmacy takes the place that trial evidence normally holds.
What this site publishes — and what it refuses to
What the evidence shows
- Trial evidence with verified NCT, PMID and DOI identifiers you can check yourself.
- Provider pricing normalised to a comparable recurring figure, with sources and capture dates.
- Explicit Verification Pending labels wherever a fact has not been confirmed.
- Public JSON and CSV datasets behind every number on the site.
What the evidence does not show
- Individualised dosing, titration, or tapering schedules — those belong to your prescriber.
- Unit-to-milligram converters or syringe calculators for compounded products.
- Rankings built on unverified fee structures or assumed pharmacy relationships.
- Paid placements — no provider can buy inclusion, position, or wording.
What data can you download?
Every figure on this site resolves to a published record. 0 of 24 provider records currently carry a normalisable tirzepatide price; the rest are marked with the reason they cannot be compared. Prices verified 2026-07-20.
Download the datasets How we verify
What does this page cover, and what does it deliberately leave out?
This page addresses Evidence, cost, provider, pharmacy, safety and research, organised around the primary question of tirzepatide. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Evidence | Covered on this page | Regulatory or policy source |
| Cost | Covered on this page | Regulatory or policy source |
| Provider | Covered on this page | Regulatory or policy source |
| Pharmacy | Covered on this page | Regulatory or policy source |
| Safety | Covered on this page | Regulatory or policy source |
| Research | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the corrections process |
What are the limits of what this page can tell you?
Every page on this site rests on a specific published policy, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the corrections process.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
None of this makes the page less useful. It makes the boundary between what is established and what is assumed visible, which is the difference between a resource that can be checked and one that must be trusted.
What would change the conclusion on this page?
Stating in advance what evidence would revise a conclusion is a discipline that separates an evidence-led position from a fixed one. If any of the following occurred, this page would be revised and the change recorded in its change history rather than edited silently.
- New primary evidence bearing directly on tirzepatide.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the terms used above, in the sense this page uses them. Terminology in this field is frequently used loosely in marketing, and several of these words carry a narrower meaning in regulatory or clinical contexts than in everyday use.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| DOI | Digital Object Identifier. A persistent link to a specific published article that continues to resolve even if the journal reorganises its website. |
| GIP | Glucose-dependent insulinotropic polypeptide. An incretin hormone released by the small intestine after eating. Tirzepatide activates its receptor alongside the GLP-1 receptor, which is the feature that distinguishes it from single-agonist drugs such as semaglutide. |
| GLP-1 | Glucagon-like peptide-1. An incretin hormone that slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin release, and suppresses inappropriate glucagon secretion. |
| PMID | PubMed Identifier. A number that locates the peer-reviewed publication of a study in the PubMed database. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| excipient | An inactive ingredient in a formulation. Excipients affect stability, tolerability, and injection-site reactions, and can differ between compounded preparations and the approved product. |
| placebo | An inactive comparator given so that the effect of the drug can be separated from the effect of being in a trial. Placebo groups in the SURMOUNT trials still lost some weight, which is why the placebo-subtracted difference matters more than the raw figure. |
| titration | The process of adjusting a drug dose over time, usually upward from a starting dose, to balance effect against tolerability. Tirzepatide titration is directed by a prescriber and is never published as a personal schedule on this site. |
Frequently asked questions
What is tirzepatide used for?
It is approved as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes, and has been studied in obstructive sleep apnoea and heart failure with preserved ejection fraction.
How much weight do people lose on tirzepatide?
About 20.9% mean reduction at 15 mg over 72 weeks in SURMOUNT-1 (without diabetes), and roughly 12.8-14.7% in SURMOUNT-2 (with type 2 diabetes).
Is compounded tirzepatide FDA approved?
No. Compounded tirzepatide is not FDA approved and is not reviewed by the FDA for safety, effectiveness, or quality before sale. No randomised trial has evaluated a compounded product.
Do you make money from the providers you rank?
No. There is no affiliate, referral, sponsorship, or ownership relationship with any provider, pharmacy, or manufacturer.
Will I regain weight if I stop?
SURMOUNT-4 found substantial regain after randomised withdrawal, while continuing treatment maintained the loss.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.